Published in J Clin Invest on January 01, 1988
Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med (1989) 10.60
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med (1993) 8.76
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med (1990) 2.79
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med (1992) 2.26
Dendritic cells stimulate primary human cytolytic lymphocyte responses in the absence of CD4+ helper T cells. J Exp Med (1990) 2.19
Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest (1993) 2.18
Production of granulocyte/macrophage-colony-stimulating factor by human natural killer cells. Modulation by the p75 subunit of the interleukin 2 receptor and by the CD2 receptor. J Clin Invest (1991) 0.98
Interactions between receptors for interleukin 2 and interleukin 4 on lines of helper T cells (HT-2) and B lymphoma cells (BCL1). J Exp Med (1989) 0.95
T-cell activation is required for efficient replication of human herpesvirus 6. J Virol (1990) 0.94
Interleukin-2 can induce suppression of human natural killer cell cytotoxicity. Clin Exp Immunol (1989) 0.78
Interleukin-2 enhances the cytotoxic activity of circulating natural killer cells in patients with chronic heart failure. Heart Vessels (2009) 0.77
Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. Clin Exp Immunol (1994) 0.75
Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother (2016) 0.75
"A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem (1984) 66.58
Cytoplasmic dot hybridization. Simple analysis of relative mRNA levels in multiple small cell or tissue samples. J Biol Chem (1982) 11.91
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol (1981) 10.92
T cell growth factor receptors. Quantitation, specificity, and biological relevance. J Exp Med (1981) 10.66
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med (1984) 6.45
Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol (1983) 6.39
Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med (1981) 5.76
Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med (1984) 5.26
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. Proc Natl Acad Sci U S A (1986) 4.61
Interleukin 2 high-affinity receptor expression requires two distinct binding proteins. J Exp Med (1987) 4.53
Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science (1986) 4.30
Interleukin-2 augments natural killer cell activity. Nature (1981) 4.15
TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J Immunol (1985) 3.18
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol (1984) 3.07
A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature (1987) 3.00
The Fc receptor for IgG on human natural killer cells: phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol (1984) 2.70
Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors. Proc Natl Acad Sci U S A (1987) 2.65
Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens. J Immunol (1985) 2.20
Human natural killer cells isolated from peripheral blood do not rearrange T cell antigen receptor beta chain genes. J Exp Med (1986) 2.01
Direct activation of human resting T cells by IL 2: the role of an IL 2 receptor distinct from the Tac protein. J Immunol (1987) 1.83
Interleukin 2 dependence of human natural killer (NK) cell activity. J Immunol (1983) 1.79
Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J Mol Cell Immunol (1985) 1.48
Effect of interleukin 1 on the expression of interleukin 2 receptor (Tac antigen) on human natural killer cells and natural killer-like cell line (YT cells). J Immunol (1986) 1.37
Isolation of B and T lymphocytes by nylon fiber columns. Tissue Antigens (1977) 1.18
Recombinant interleukin 2 and gamma-interferon act synergistically on distinct steps of in vitro terminal human B cell maturation. J Clin Invest (1986) 0.99
Recombinant interleukin-2-induced polyclonal proliferation of in vitro unstimulated human peripheral blood lymphocytes. Cell Immunol (1986) 0.98
Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: contribution of large granular lymphocytes and T lymphocytes. Cell Immunol (1986) 0.96
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (1993) 15.54
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med (1992) 13.29
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (1986) 11.74
Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med (1983) 10.09
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med (1986) 9.86
Cloning and expression of murine interleukin-1 cDNA in Escherichia coli. Nature (1985) 9.81
A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor. Nature (1982) 9.42
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
NF-kappa B controls expression of inhibitor I kappa B alpha: evidence for an inducible autoregulatory pathway. Science (1993) 9.03
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum (1990) 8.92
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum (1990) 8.67
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum (1990) 8.36
Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum (1990) 8.23
The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science (1989) 7.90
Toward an understanding of the correlates of protective immunity to HIV infection. Science (1996) 7.59
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med (1978) 7.17
Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science (2001) 6.79
Biological and biochemical characterization of a cloned Leu-3- cell surviving infection with the acquired immune deficiency syndrome retrovirus. J Exp Med (1986) 6.52
Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. N Engl J Med (1985) 6.46
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Low and high affinity cellular receptors for interleukin 2. Implications for the level of Tac antigen. J Exp Med (1984) 6.45
Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci U S A (1989) 6.32
Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A (1989) 6.32
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Takayasu arteritis. Ann Intern Med (1994) 5.94
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
The same inducible nuclear proteins regulates mitogen activation of both the interleukin-2 receptor-alpha gene and type 1 HIV. Cell (1988) 5.33
New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med (1993) 5.32
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A (1999) 5.25
Activation of the HIV-1 LTR by T cell mitogens and the trans-activator protein of HTLV-I. Science (1987) 5.22
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol (1986) 5.19
Glucocorticosteroid therapy: mechanisms of action and clinical considerations. Ann Intern Med (1976) 5.16
Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus. J Virol (1986) 5.05
Regulatory pathways governing HIV-1 replication. Cell (1989) 4.97
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J Clin Invest (1974) 4.90
Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89
The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell (1990) 4.87
Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med (2000) 4.83
Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med (1999) 4.81
Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med (1988) 4.81
Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A (1990) 4.80
HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science (1988) 4.77
Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med (1996) 4.72
NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med (1982) 4.70
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum (1990) 4.43
Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 4.23
HIV. An elusive soluble suppressor. Nature (1995) 4.18
Sjögren's syndrome (Sicca syndrome): current issues. Ann Intern Med (1980) 3.81
Induction of HTLV-III/LAV from a nonvirus-producing T-cell line: implications for latency. Science (1986) 3.80
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Interleukin 2 (IL-2) augments transcription of the IL-2 receptor gene. Proc Natl Acad Sci U S A (1985) 3.74
Identification of HTLV-I tax trans-activator mutants exhibiting novel transcriptional phenotypes. Genes Dev (1990) 3.67
Re-emergence of HIV after stopping therapy. Nature (1999) 3.54
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature (1990) 3.50
Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression. Science (1989) 3.48
Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol (1988) 3.45
Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci U S A (1989) 3.43
Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science (1989) 3.43
Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc Natl Acad Sci U S A (1987) 3.43
Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science (2001) 3.37
Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis (1997) 3.35
Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein. Nature (1988) 3.31
Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood (1988) 3.30
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol (1986) 3.29
Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J (1993) 3.28
Expression of interleukin 2 receptors on activated human B cells. J Exp Med (1984) 3.27
Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science (1984) 3.20
Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol (1985) 3.19
Tumor necrosis factor alpha functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A (1990) 3.18
Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis (1991) 3.16
Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol (1986) 3.12
Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines. J Exp Med (1998) 3.11
Comparative analysis of the HTLV-I Rex and HIV-1 Rev trans-regulatory proteins and their RNA response elements. Genes Dev (1989) 3.09
The 65-kDa subunit of human NF-kappa B functions as a potent transcriptional activator and a target for v-Rel-mediated repression. Proc Natl Acad Sci U S A (1992) 3.09
Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol (1978) 3.07
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
Sequential expression of genes involved in human T lymphocyte growth and differentiation. J Exp Med (1985) 3.04
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol (1981) 3.02
Tumor necrosis factor alpha induces proteins that bind specifically to kappa B-like enhancer elements and regulate interleukin 2 receptor alpha-chain gene expression in primary human T lymphocytes. Proc Natl Acad Sci U S A (1989) 3.00
Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A (1999) 3.00
A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors. Nature (1987) 3.00